Gapping up
In reaction to earnings/guidance: CCRN +24.4%, PCOM +21%, SD +16.9%, CDXS +16.4%, MHGC +14.8%, BOJA +13.6%, AHS +13.4%, SCSS +13.1%, SEDG +10.9%, FLT +8.3%, MRIN +8.1%, HABT +8%, GDDY +7.7%, MELI +7.5%, TXMD +7%, HDSN +5.9%, POWR +5.8%, BRKR +5.7%, LNTH +5.7%, XPO +5.5%, ACAS +5.1%, OSUR +4.9%, FB +4.8%, MATR +3.7%, HUBS+3.6%, KW +2.9%, COHR +2.8%, LFVN +2.8%, AHT +2.2%, BREW +2.1%, MCHP +2%, OME +1.8%, CLR +1.8%, CTL +1.6%, SUN +1.5%, UHAL +1.4%, IMH +1.3%, TNH +1.2%, WSR +1.1%, PSEC +1%
M&A news: SD +16.9% (acquired the assets of EE3 for $190 mln in cash, adds 136,000 largely contiguous net acres and multiyear niobrara shale drilling inventory in North Park Basin, Colorado; co also reported earnings), AWAY +23.3% (HomeAway to be acquired by Expedia (EXPE) for $38.31/share, or ~$3.9 bln), EXPE +4.1%
Other news: NRX +13.3% (announced successful results from a preclinical toxicity study of intravenous Pyridorin), ETRM +10.3% (presents two year follow up results from the ReCharge Study of vBloc Neurometabolic Therapy in obesity ), OASM +4.8% (confirms the previously published findings from a head-to-head comparison study of its lead human cancer product Paclical and Celgene's Abraxane), INO +4.7% (reports interim data analysis showing that its INO-3112 DNA-based immunotherapy generated specific T-cell responses), RXII +4.5% (initiates a Phase 1/2 clinical trial of RXI-109, as a potential treatment to prevent the progression of retinal scarring), EXPE +4.1% (HomeAway to be acquired by Expedia (EXPE) for $38.31/share, or ~$3.9 bln), ADSK +3.7% (: Sachem Head Capital Management discloses 5.7% active stake in 13D filing; Sachem Head intends to engage with management ), GLUU +3.2% (Integrated Core Strategies (Millennium International Management) discloses 5.2% passive stake in 13G filing), .
Analyst comments: ISIS +3% (upgraded to Overweight from Neutral at Piper Jaffray), MCHP +2% (upgraded to Buy from Neutral at B. Riley & Co), SHOP +1.9% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)
In reaction to earnings/guidance: CCRN +24.4%, PCOM +21%, SD +16.9%, CDXS +16.4%, MHGC +14.8%, BOJA +13.6%, AHS +13.4%, SCSS +13.1%, SEDG +10.9%, FLT +8.3%, MRIN +8.1%, HABT +8%, GDDY +7.7%, MELI +7.5%, TXMD +7%, HDSN +5.9%, POWR +5.8%, BRKR +5.7%, LNTH +5.7%, XPO +5.5%, ACAS +5.1%, OSUR +4.9%, FB +4.8%, MATR +3.7%, HUBS+3.6%, KW +2.9%, COHR +2.8%, LFVN +2.8%, AHT +2.2%, BREW +2.1%, MCHP +2%, OME +1.8%, CLR +1.8%, CTL +1.6%, SUN +1.5%, UHAL +1.4%, IMH +1.3%, TNH +1.2%, WSR +1.1%, PSEC +1%
M&A news: SD +16.9% (acquired the assets of EE3 for $190 mln in cash, adds 136,000 largely contiguous net acres and multiyear niobrara shale drilling inventory in North Park Basin, Colorado; co also reported earnings), AWAY +23.3% (HomeAway to be acquired by Expedia (EXPE) for $38.31/share, or ~$3.9 bln), EXPE +4.1%
Other news: NRX +13.3% (announced successful results from a preclinical toxicity study of intravenous Pyridorin), ETRM +10.3% (presents two year follow up results from the ReCharge Study of vBloc Neurometabolic Therapy in obesity ), OASM +4.8% (confirms the previously published findings from a head-to-head comparison study of its lead human cancer product Paclical and Celgene's Abraxane), INO +4.7% (reports interim data analysis showing that its INO-3112 DNA-based immunotherapy generated specific T-cell responses), RXII +4.5% (initiates a Phase 1/2 clinical trial of RXI-109, as a potential treatment to prevent the progression of retinal scarring), EXPE +4.1% (HomeAway to be acquired by Expedia (EXPE) for $38.31/share, or ~$3.9 bln), ADSK +3.7% (: Sachem Head Capital Management discloses 5.7% active stake in 13D filing; Sachem Head intends to engage with management ), GLUU +3.2% (Integrated Core Strategies (Millennium International Management) discloses 5.2% passive stake in 13G filing), .
Analyst comments: ISIS +3% (upgraded to Overweight from Neutral at Piper Jaffray), MCHP +2% (upgraded to Buy from Neutral at B. Riley & Co), SHOP +1.9% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)